Medical/Pharmaceuticals
Doer Biologics Announces First Subject Dosed in Phase I 12-Week Multiple-Ascending Dose (MAD) Clinical Trial of DR10624 and Received IND Approval From NMPA
HANGZHOU, China, Aug. 1, 2023 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...
2023-08-01 17:08
1797
Hybribio showcased cutting-edge cervical cancer HPV diagnostic solutions at ADLM 2023
ANAHEIM, Calif., July 31, 2023 /PRNewswire/ -- Hybribio (300639.SZ) exhibited live at the 75th ADLM (former AACC) Annual Scientific Meeting & Clinical Lab Expo,July 25-27, at Anaheim Convention Center, California, USA. This event attracted 958 exhibitors and over 70,000 attendees worldwide from d...
2023-08-01 01:00
2958
Seegene unveils solutions to popularize molecular diagnostics at 2023 AACC
* Introduced syndromic quantitative PCR assays and a fully automated molecular diagnostic testing system, STARlet AIOS™ * Conducted symposium sessions on the usefulness of PCR testing in diagnosing gastrointestinal diseases * Participated in a presentation event for major Korean in-vitro dia...
2023-08-01 00:00
2537
Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together
BOSTON, July 31, 2023 /PRNewswire/ -- On July 25, 2023, Fosun Health Capital established by Fosun Pharma (stock code:600196.SH), reached a strategic partnership with Medicilon (stock code: 688202.SH). Meanwhile StarMab Biology (Suzhou) (jointly invested by the innovation drug research fund of Fo...
2023-07-31 20:30
3205
WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022
* Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 39.5% * Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year; Excluding COVID-19 Commercial Projects, Up 27.9% * Net Profit Attributable to Owners of the Co...
2023-07-31 18:02
5284
111 to Announce Second Quarter 2023 Unaudited Financial Results on August 24, 2023 - Conference Call to Follow
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial result...
2023-07-31 17:59
2578
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI-045B in Atopic Dermatitis (ADAMANT)
NEWARK, N.J. and NANJING, China, July 31, 2023 /PRNewswire/ -- Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . "We are pleas...
2023-07-31 17:05
4522
GLOBAL SARCOMA THERAPY NOW LISTED ON PHARMACEUTICAL BENEFITS SCHEME
* YONDELIS® (trabectedin) now PBS listed for Australian patients * Listing described as "wonderful news" for patients living with rare lipo and leiomyo sarcomas * YONDELISÒ (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 SINGAPORE, July 31...
2023-07-31 15:00
2630
U.S. FDA Accepts Biologics License Application for GC Biopharma's GC5107B (Immune Globulin Intravenous (Human), 10% Liquid)
YONGIN, South Korea, July 31, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company dedicated to specialty plasma-derived therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's resubmission of the Biologics License App...
2023-07-31 13:20
2460
J INTS BIO, Novel Oral 4th Generation EGFR TKI 'JIN-A02' - Dosing of First Patient in the Global Multi-center Phase 1/2 Clinical Study began
SEOUL, South Korea, July 31, 2023 /PRNewswire/ -- J INTS BIO announced the
successful dosing of the first patient in its global multi-center Phase 1/2
clinical study of 'JIN-A02' on 31st July at Severance Hospital, Seoul, Korea.
2023-07-31 13:10
1943
Akeso Inc. Published 2023 Interim Results Positive Profit Alert
HONG KONG, July 31, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, today announced that it is expected that the Company will r...
2023-07-31 12:33
4563
NMPA and FDA Approved the First-in-Human Clinical Trial Applications to Evaluate LBL-034, An Anti-GPRC5D/CD3 Bispecific Antibody Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma
NANJING, China, July 31, 2023 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investi...
2023-07-31 12:09
1763
VARON Reiterates Its Commitment to Brand Value and Its Determination to Reshape the Oxygen Concentrator Industry
SEATTLE, July 28, 2023 /PRNewswire/ -- VARON
2023-07-28 22:20
3275
HANQUYOU Marks 3rd Anniversary with Brilliant Achievements
* HANQUYOU is the China-developed biosimilar with the most marketing approvals, covering 41 countries and regions * The launch of HANQUYOU kicks off the competition between Chinese pharmaceutical companies and the world's bio-pharmaceutical companies in biosimilar monoclonal antibodies * He...
2023-07-28 15:27
3478
Wuan Ankang Hospital's Innovative Tumor Treatment Attracts Many Patients
HANDAN, China, July 28, 2023 /PRNewswire/ -- In Handan City, Hebei Province, China, the Wu'an Ankang Hospital has 35-year of experience with tumor treatment. It has now become a second-class general hospital. The reason it attracts many patients from bothChina and abroad is that they practice hol...
2023-07-28 14:35
1643
Empowering Regenerative Medicine: 3A-GTP Technology Ushers in a New Epoch
Pioneering Green Energy Solutions: DrSignal Biotech and J&V Energy's Promising Alliance TAIPEI, July 27, 2023 /PRNewswire/ -- At the 2022 Healthcare Expo Taiwan, Dr.Signal Biotech showcased the remarkable 3A-GTP technology, succeeding a significant breakthrough. This technology accelerates the p...
2023-07-28 10:00
2293
HanAll Biopharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
* Sales recorded KRW 41.4 billion, a 58 percent increase from the same period in 2022, due to sustained robust growth of major products in addition to milestone revenues from the progress in clinical programs of batoclimab. * Multiple clinical development milestones have been reached, includin...
2023-07-27 19:00
2647
AI Medical Service Inc. Signs Joint Research Agreement with Stanford Medicine
- AIM Is First Japanese Company to Establish Joint Research Agreement in Field of Endoscopic AI - TOKYO, July 27, 2023 /PRNewswire/ -- AI Medical Service Inc. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has signed a joint research agreement ...
2023-07-27 14:00
1801
GC Genome enables the prognosis prediction and targeted treatment in breast cancer patients
YONGIN, South Korea, July 26, 2023 /PRNewswire/ -- GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Journal of the National Cancer Institute (JNCI), shedding light on the remarkable potential of utilizing circulating tumor DNA (ctDNA) copy n...
2023-07-27 08:53
1773
PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
DAEJEON, South Korea, July 26, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Compa...
2023-07-26 20:00
2745
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 289 media titles]
2026-09-22 18:37
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 276 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 273 media titles]
2026-09-21 08:00Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
10800
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
9931
Ohmyhome Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2026-09-17 20:00
8140
American Savings Bank Jumps More Than 6% in Trading Debut: NYSE Content Update
2026-09-17 21:21
7722
Sea, Gardens, Lawns and Hearths: Life Abroad Across Noah's N+ Club Network
2026-09-18 23:04
7012